|
|
||||||||||
|
J Am Coll Cardiol, 2001; 37:434-439 © 2001 by the American College of Cardiology Foundation |


* Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Münster, Germany
Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany
Manuscript received June 7, 2000; revised manuscript received August 23, 2000, accepted October 4, 2000.
Reprint requests and correspondence: Dr. Arnold von Eckardstein, Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany
vonecka{at}unimuenster.de
OBJECTIVES
This prospective population study was conducted to assess the role of elevated lipoprotein(a) [Lp(a)] as a coronary risk factor.
BACKGROUND
The role of elevated Lp(a) as a risk factor for coronary heart disease is controversial. In addition, little attention has been paid to the interaction of Lp(a) with other risk factors.
METHODS
A total of 788 male participants of the Prospective Cardiovascular Münster (PROCAM) study aged 35 to 65 years were followed for 10 years. Both Lp(a) and traditional cardiovascular risk factors (e.g., age, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure, cigarette smoking, diabetes mellitus, angina pectoris, and family history of myocardial infarction) were evaluated in 44 men who suffered from myocardial infarction, and in 744 men who survived without major coronary events or stroke. A multiple logistic function algorithm was used to estimate global cardiovascular risk by the combined effects of traditional risk factors.
RESULTS
Overall, the risk of a coronary event in men with an Lp(a)
0.2 g/liter was 2.7 times that of men with lower levels (95% confidence interval [CI]: 1.4 to 5.2). This increase in risk was most prominent in men with LDL cholesterol level
4.1 mmol/liter (relative risk [RR]: 2.6; 95% CI: 1.2 to 5.7), with HDL cholesterol
0.9 mmol/liter (RR 8.3; 95% CI: 2.0 to 35.5), with hypertension (RR 3.2; 95% CI: 1.4 to 7.2), or within the two highest global risk quintiles (relative risk: 2.7; 95% CI: 1.3 to 5.7).
CONCLUSIONS
Lp(a) increases the coronary risk, especially in men with high LDL cholesterol, low HDL cholesterol, hypertension and/or high global cardiovascular risk.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
L. Berglund and E. Anuurad Role of Lipoprotein(a) in Cardiovascular Disease: Current and Future Perspectives J. Am. Coll. Cardiol., July 8, 2008; 52(2): 132 - 134. [Full Text] [PDF] |
||||
![]() |
P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study Circulation, January 15, 2008; 117(2): 176 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rippe, T. J. Angelopoulos, and L. Zukley The Rationale for Intervention to Reduce the Risk of Coronary Heart Disease American Journal of Lifestyle Medicine, January 1, 2007; 1(1): 10 - 19. [Abstract] [PDF] |
||||
![]() |
M. J. Bos, C. M. A. Schipper, P. J. Koudstaal, J. C.M. Witteman, A. Hofman, and M. M.B. Breteler High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study Circulation, October 10, 2006; 114(15): 1591 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Assmann Dyslipidaemia and global cardiovascular risk: clinical issues Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F40 - F46. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA, September 20, 2006; 296(11): 1363 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shai, E. B. Rimm, S. E. Hankinson, C. Cannuscio, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur. Heart J., August 2, 2005; 26(16): 1633 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Assmann Calculating global risk: the key to intervention Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F9 - F14. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hernandez, G. Francisco, P. Chacon, and R. Simo Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study Diabetes Care, April 1, 2005; 28(4): 931 - 933. [Full Text] [PDF] |
||||
![]() |
R. Guerra, Z. Yu, S. Marcovina, R. Peshock, J. C. Cohen, and H. H. Hobbs Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study Circulation, March 29, 2005; 111(12): 1471 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A Enas, A. Senthilkumar, C. Vinod, and N. Puthumana Dyslipidaemia among Indo-Asians strategies for identification and management The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 81 - 90. [Abstract] [PDF] |
||||
![]() |
K. Hoffmann, B.-C. Zyriax, H. Boeing, and E. Windler A dietary pattern derived to explain biomarker variation is strongly associated with the risk of coronary artery disease Am. J. Clinical Nutrition, September 1, 2004; 80(3): 633 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rifai, J. Ma, F. M. Sacks, P. M. Ridker, W. J. L. Hernandez, M. J. Stampfer, and S. M. Marcovina Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study Clin. Chem., August 1, 2004; 50(8): 1364 - 1371. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF] |
||||
![]() |
A. von Eckardstein Is there a need for novel cardiovascular risk factors? Nephrol. Dial. Transplant., April 1, 2004; 19(4): 761 - 765. [Full Text] [PDF] |
||||
![]() |
A. von Eckardstein Novel Risk Factors for Atherosclerosis JAMA, January 21, 2004; 291(3): 301 - 301. [Full Text] [PDF] |
||||
![]() |
D. G. Hackam and S. S. Anand Novel Risk Factors for Atherosclerosis--Reply JAMA, January 21, 2004; 291(3): 301 - 302. [Full Text] [PDF] |
||||
![]() |
S. M. Marcovina, M. L. Koschinsky, J. J. Albers, and S. Skarlatos Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions Clin. Chem., November 1, 2003; 49(11): 1785 - 1796. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tsiara, M. Elisaf, and D. P. Mikhailidis Influence of Smoking on Predictors of Vascular Disease Angiology, September 1, 2003; 54(5): 507 - 530. [Abstract] [PDF] |
||||
![]() |
E. S. Ganotakis, K. Mandalaki, M. Tampakaki, N. Malliaraki, E. Mandalakis, G. Vrentzos, J. Melissas, and E. Castanas Subclinical Hypothyroidism and Lipid Abnormalities in Older Women Attending a Vascular Disease Prevention Clinic: Effect of Thyroid Replacement Therapy Angiology, September 1, 2003; 54(5): 569 - 576. [Abstract] [PDF] |
||||
![]() |
D. G. Hackam and S. S. Anand Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence JAMA, August 20, 2003; 290(7): 932 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF] |
||||
![]() |
A. von Eckardstein, P. Cullen, and G. Assmann Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent): Reply J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1584 - 1585. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |